CAS 1443530-05-9

Rogaratinib

CAS : 1443530-05-9

Rogaratinib

Degré de pureté : ≥98%

Masse moléculaire : 466.56g/mol

Ref: 54-BUP21863

Rogaratinib

CAS : 1443530-05-9

Rogaratinib is a kinase inhibitor drug that is used to treat hyperproliferative disease, such as cancer. It inhibits the epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR). Rogaratinib has been shown to inhibit the proliferation of carcinoma cells. It also has an inhibitory effect on proximal tubules in the kidney and bladder. Rogaratinib is a potent inhibitor of PDGFR, but with limited activity against EGFR. This drug also binds tightly to platinum-based chemotherapy drugs, which may be useful for treating cancers that are resistant to other types of therapy.

Formule : C₂₃H₂₆N₆O₃S

Degré de pureté : Min. 95%

Couleur et forme : Powder

Masse moléculaire : 466.56 g/mol

Ref: 3D-THC53005

Rogaratinib

CAS : 1443530-05-9

Rogaratinib (BAY1163877) is an aberrant inhibitor of fibroblast growth factor receptor (FGFR).

Formule : C₂₃H₂₆N₆O₃S

Degré de pureté : 99.54%

Couleur et forme : Solid

Masse moléculaire : 466.56

Ref: TM-T16781